Your search returned 4 results.

Results
	1.	Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer. MedStar authors: McCarron, Edward C PMID: 38301187 Year: 2024 Citation: Journal of Clinical Oncology. 42(11):1288-1300, 2024 Apr 10. Institution: MedStar Franklin Square Medical Center Medline publication type: Clinical Trial, Phase III Journal Article Randomized Controlled Trial Form of publication: Journal Article All authors: Ganz PA, Bandos H, Spanic T, Friedman S, Muller V, Kuemmel S, Delaloge S, Brain E, Toi M, Yamauchi H, de Duenas EM, Armstrong A, Im SA, Song CG, Zheng H, Sarosiek T, Sharma P, Geng C, Fu P, Rhiem K, Frauchiger-Heuer H, Wimberger P, t'Kint de Roodenbeke D, Liao N, Goodwin A, Chakiba-Brugere C, Friedlander M, Lee KS, Giacchetti S, Takano T, Henao-Carrasco F, Virani S, Valdes-Albini F, Domchek SM, Bane C, McCarron EC, Mita M, Rossi G, Rastogi P, Fielding A, Gelber RD, Scheepers ED, Cameron D, Garber J, Geyer CE, Tutt ANJ DOI: Click here to access online Add to cart (remove)
	2.	Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines. MedStar authors: Asch, Federico M Barac, Ana Herbolsheimer, Pia M Lynce, Filipa Mete, Mihriye Nunes, Raquel Shara, Nawar M Swain, Sandra M Wray, Lynette PMID: 26749359 Year: 2016 Citation: Breast Cancer Research & Treatment. 155(2):285-93, 2016 Jan. Institution: MedStar Health Research Institute MedStar Health Research Institute MedStar Health Research Institute MedStar Washington Hospital Center MedStar Washington Hospital Center Washington Cancer Institute Washington Cancer Institute Washington Cancer Institute A Washington Cancer Instituteia Department: MedStar Heart Institute MedStar Heart Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Asch FM, Barac A, Herbolsheimer P, Isaacs C, Lynce F, Mete M, Nardacci MP, Nunes RA, Peshkin BN, Shara NM, Smith KL, Swain SM, Warren R, Wray L Add to cart (remove)
	3.	Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. MedStar authors: Swain, Sandra M PMID: 25332247 Year: 2014 Citation: Journal of Clinical Oncology. 32(33):3753-61, 2014 Nov 20. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Baselga J, Clark E, Cortes J, Im SA, Kiermaier A, Ross G, Swain SM DOI: http://dx.doi.org/10.1200/JCO.2013.54.5384 Add to cart (remove)
	4.	Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. MedStar authors: Swain, Sandra M PMID: 25559813 Year: 2015 Citation: Journal of Clinical Oncology. 33(12):1340-7, 2015 Apr 20. Institution: Washington Cancer Institute Medline publication type: Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Blackmon NL, Costantino JP, Fehrenbacher L, Finnigan M, Gavin PG, Geyer CE Jr, Jeong JH, Kim SR, Mamounas EP, Paik S, Pogue-Geile KL, Rastogi P, Song N, Swain SM, Wickerham DL, Wolmark N DOI: http://dx.doi.org/10.1200/JCO.2014.56.2439 Add to cart (remove)

Powered by Koha